Althera Pharms Drug Patent Portfolio
Althera Pharms owns 1 orange book drug protected by 2 US patents Given below is the list of Althera Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376470 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases | 01 May, 2033 | Active |
| US9763885 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases | 01 May, 2033 | Active |
Latest Legal Activities on Althera Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Althera Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Feb, 2023 | US10376470 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 08 Oct, 2021 | US9763885 |
|
Email Notification
Critical
| 08 Oct, 2021 | US10376470 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 08 Oct, 2021 | US10376470 |
|
Email Notification
Critical
| 08 Oct, 2021 | US9763885 |
|
Correspondence Address Change
Critical
| 06 Oct, 2021 | US10376470 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Nov, 2020 | US9763885 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 13 Aug, 2019 | US10376470 |
|
Recordation of Patent Grant Mailed
Critical
| 13 Aug, 2019 | US10376470 |
|
Email Notification
Critical
| 25 Jul, 2019 | US10376470 |
|
Issue Notification Mailed
Critical
| 24 Jul, 2019 | US10376470 |
| Dispatch to FDC | 03 Jul, 2019 | US10376470 |
| Filing Receipt - Corrected | 26 Jun, 2019 | US10376470 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Jun, 2019 | US10376470 |
|
Email Notification
Critical
| 26 Jun, 2019 | US10376470 |
Althera Pharms's Family Patents
Althera Pharms drugs have patent protection in a total of 9 countries. It's US patent count contributes only to 42.9% of its total global patent coverage. Click
below to unlock the full patent family tree.
Althera Pharms Drug List
Given below is the complete list of Althera Pharms's drugs and the patents protecting them.
1. Roszet
Roszet is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376470 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
01 May, 2033
(8 years from now)
| Active |
| US9763885 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
01 May, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Roszet's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List